Pfizer Inc
SGO:PFE
Relative Value
The Relative Value of one
PFE
stock under the Base Case scenario is
64.34
USD.
Compared to the current market price of 49.19 USD,
Pfizer Inc
is
Undervalued by 24%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
PFE Competitors Multiples
Pfizer Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Pfizer Inc
SGO:PFE
|
158B USD | 2.5 | 20.3 | 7.5 | 10.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
960.1B USD | 14.7 | 46.5 | 31.4 | 33.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579.4B USD | 6.2 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
281.2B CHF | 4.6 | 29.9 | 12.6 | 14.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228.3B GBP | 5.5 | 33.7 | 16 | 23.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
235.6B CHF | 5.4 | 21.7 | 13.4 | 17.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD | 4.5 | 16.2 | 10.1 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.2 | 9.7 | 11.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.2B USD | 2.5 | 17.3 | 6.8 | 8.7 | |
| UK |
|
GSK plc
XETRA:GS71
|
100.9B EUR | 2.7 | 15.4 | 7.8 | 11.1 |